Acalabrutinib
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
ACALABRUTINIB: Drug Repurposing Evaluation — Insufficient Prediction Data
One-Sentence Summary
Acalabrutinib is a selective Bruton's tyrosine kinase (BTK) inhibitor, approved internationally for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). The TxGNN model has not yet generated any predicted new indications for this drug. With 0 clinical trials, 0 publications, and no prediction scores available in this evidence pack, the current data is insufficient to proceed with a repurposing evaluation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this evidence pack (internationally approved for CLL/SLL/MCL) |
| Predicted New Indication | — (No TxGNN prediction available) |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (No prediction or supporting studies) |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, the TxGNN model has not produced any predicted new indications for Acalabrutinib, so a mechanistic plausibility analysis cannot be performed at this time.
For background, Acalabrutinib is a second-generation, highly selective, irreversible BTK inhibitor. BTK plays a critical role in B-cell receptor (BCR) signaling, which drives the survival and proliferation of malignant B-cells. By covalently binding to BTK, acalabrutinib blocks downstream signaling cascades (including NF-κB, ERK, and PI3K pathways), leading to inhibition of B-cell proliferation and survival. Its improved selectivity over first-generation BTK inhibitors (e.g., ibrutinib) results in fewer off-target effects on kinases such as EGFR, ITK, and TEC.
Note: The mechanism of action (MOA) was not included in the evidence pack and has been supplemented from general pharmacological knowledge. The DrugBank record (DB11703) should be queried for formal MOA documentation.
Clinical Trial Evidence
Currently no related clinical trials registered in this evidence pack.
No predicted indication was generated by TxGNN; therefore, no indication-specific clinical trial search was conducted.
Literature Evidence
Currently no related literature available in this evidence pack.
No predicted indication was generated by TxGNN; therefore, no indication-specific literature search was conducted.
Taiwan Market Information
Acalabrutinib is not currently marketed in Taiwan. No TFDA licenses were found.
| Item | Content |
|---|---|
| TFDA Authorization | None (0 licenses) |
| Market Status | 未上市 (Not marketed) |
Note: Acalabrutinib is marketed internationally under the brand name Calquence® (AstraZeneca) and has received approvals from the US FDA, EMA, and other regulatory authorities for CLL/SLL and MCL.
Cytotoxicity
Acalabrutinib is an antineoplastic agent (BTK inhibitor class, targeted therapy).
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (Bruton's tyrosine kinase inhibitor) |
| Myelosuppression Risk | Moderate — cytopenias (neutropenia, anemia, thrombocytopenia) are reported adverse effects |
| Emetogenicity Classification | Low (oral small molecule; minimal/low emetogenic potential) |
| Monitoring Items | CBC with differential, hepatic function, signs of infection, bleeding events, atrial fibrillation/flutter, second primary malignancies |
| Handling Protection | Standard oral anticancer agent handling; no special cytotoxic handling regulations required (non-cytotoxic targeted agent) |
Note: Cytotoxicity data was supplemented from general pharmacological knowledge as the evidence pack did not include toxicity details. Please refer to the Calquence® package insert for complete prescribing information.
Safety Considerations
Please refer to the package insert for safety information.
Key safety signals known from international labelling include:
- Serious infections (including opportunistic infections)
- Hemorrhage (including major bleeding events)
- Atrial fibrillation/flutter
- Second primary malignancies
- Hepatitis B reactivation
These are supplemented from general knowledge; the evidence pack did not contain TFDA-specific safety data.
Conclusion and Next Steps
Decision: Hold
Rationale: No TxGNN-predicted new indications are currently available for Acalabrutinib. Additionally, the drug is not marketed in Taiwan (0 TFDA licenses), and core safety data (package insert warnings, contraindications, DDI) have not been populated in the evidence pack. Without a predicted indication and baseline regulatory/safety data, a repurposing evaluation cannot proceed.
To proceed, the following is needed:
- TxGNN prediction run — Execute the TxGNN model for Acalabrutinib (DB11703) to generate candidate new indications with prediction scores
- MOA data — Query the DrugBank API for formal mechanism of action documentation (addresses Data Gap DG002)
- TFDA package insert — Obtain and parse the Taiwan package insert for warnings, contraindications, and safety information (addresses Data Gap DG001)
- DDI data — Obtain drug-drug interaction data from DrugBank or other interaction databases
- Taiwan regulatory pathway assessment — Given the drug is not marketed in Taiwan, evaluate whether an importation or compassionate use pathway would be applicable for any future repurposing indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.